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Abstract
MicroRNAs (miRNAs) are essential post-transcriptional regulators that determine cell identity and
fate. Aberrant expression of miRNAs can lead to diseases, including cancer. Expression of many
miRNAs in the de-differentiated brain tumor cancer stem cells resembles that of neural stem cells.
In this issue of BMC Medicine, Silber et al provide evidence of the expression of such miRNAs and
their potential to mediate differentiation in both stem cell populations. In this commentary, we
discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and
how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in
glioblastomas.
MicroRNA biogenesis and function
With over 500 microRNA (miRNA) genes identified
experimentally in the human genome and a plethora of
computationally predicted mRNA targets, it is believed
that these small non-coding RNAs have a central role in
diverse cellular and developmental processes. miRNAs
function as endogenous triggers of the RNA interference
pathway. When mature (active) they are ~22 nt small
RNAs, generated by two cleavage steps, which are cata-
lyzed by two distinct complexes: Drosha, which is found
in the nucleus, and Dicer, which is found in the cytoplasm
(Figure 1) [1]. Following Dicer cleavage, the mature form
of the miRNA is incorporated into the RNA-induced
silencing complex (RISC) where the 3' untranslated
region (3'-UTR) of the target mRNA associates with the
major component of the RISC complex, Argonaute (Fig-
ure 1) [1].
miRNAs act on cellular transcripts by two different mech-
anisms. The first mechanism is cleavage-dependent RNA
degradation of the transcript at the site where the miRNA
binds. The other mechanism is miRNA-mediated transla-
tional repression of the target transcript, while the miRNA
binds to the target 3'-UTR with several mismatches. This
partial complementarity allows for miRNAs to target mul-
tiple 3'-UTRs [1]. A key question that arises from the tar-
geting of multiple transcripts is whether there has been
evolutionary enrichment in targets that are involved in
similar cellular functions.
miRNAs in cancer
Aberrant expression of miRNA genes can lead to human
diseases, including cancer. In recent years, a number of
informative profiling studies have determined the levels
of miRNAs in various types of cancer cell lines and tumors
[2]. Most of these studies have identified multiple dysreg-
ulated miRNAs, which in many cases can classify cancer
types [3]. In addition, multiple functional studies on
tumor suppressive or oncogenic miRNAs were identified
from profiling, screens or due to their cancer-associated
genomic loci [2,3].
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The first tumor suppressive miRNAs identified were the
miR-15/miR-16  cluster, located in a genomic region of
chr13, which is often deleted in chronic lymphocytic
leukemias (CLLs). Therefore, these two miRNAs are not
expressed in CLLs, leading to increased levels of an onco-
genic target, the apoptotic inhibitor Bcl-2 [2].
The first functional evidence of a miRNA, or a non-coding
RNA, acting as a mammalian 'oncogene' or 'onco-miR'
was the miR-17–92 polycistron. Enforced expression of
this 'onco-miR' was shown to act with c-Myc to accelerate
tumor development in a mouse B-cell lymphoma model
[4]. c-Myc, which is a well-studied oncogene, activates the
expression of miR-17–92  through its direct interaction
with the putative promoter region. This finding could
explain the high expression levels of the miRNA cluster in
lung, breast, stomach, prostate, colon and pancreatic can-
cers where it potentially plays a similar oncogenic role
[2,5]. miRNAs from this cluster target tumor suppressor
genes such as E2F1, PTEN and TGFβRII [2,5].
Gliomas are the most common primary tumors in the
brain and are divided into four clinical grades on the basis
of their histology and prognosis. Grade IV Glioblastomas
are the most malignant of all brain tumors and are almost
always fatal [6,7]. Profiling of glioblastoma tumors and
cell lines has revealed increased levels of miR-21 [8]. In
the same study, inhibition of miR-21 in glioblastoma cells
led to increased cell death, suggesting that miR-21 could
be acting as an oncogene to inhibit cell death in glioblas-
tomas. Subsequent cancer profiling studies also reported
increased levels of miR-21 in most types of cancer where
miR-21 had the same anti-apoptotic role [2]. Recently, a
study determined that miR-21 knockdown in glioblast-
oma cells significantly repressed the ability of these cells
to form tumors in an in vivo mouse xenograft model [9].
In this issue of BMC Medicine, a study by Silber et al dem-
onstrates that two miRNAs, miR-124 and miR-137, are
significantly decreased in anaplastic astrocytomas (AA,
WHO grade III) and glioblatoma multiforme (GBM,
WHO grade IV) relative to non-neoplastic brain tissue. In
MicroRNA biogenesis Figure 1
MicroRNA biogenesis. Primary transcripts are transcribed from the genome and form a long hairpin loop, pri-miRNA, 
which is processed by Drosha to form pre-miRNA. Pre-miRNA is exported to the cytoplasm by Exportin 5 where Dicer 
cleaves off the hairpin loop to form a duplex that contains the mature 21–23 nucleotide microRNA (miRNA). The mature 
miRNA is then incorporated into the RNA-induced silencing complex to target the 3' untranslated region of the target mRNA.BMC Medicine 2008, 6:15 http://www.biomedcentral.com/1741-7015/6/15
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addition to the profiling performed in this study, in situ
hybridization experiments would be helpful to determine
the exact cell populations in which miR-124 and miR-137
are dysregulated. When these miRNAs were overexpressed
in glioblastoma cell lines, they led to G1 cell cycle arrest
by repression of Retinoblastoma (RB) and CDK6. Down-
regulation of CDK6 occurs partially through direct target-
ing by miR-137. This is a significant tumor suppressive
potential of these two miRNAs by repressing cell cycle
progression and thus the growth of GBM cells.
microRNAs in cancer stem cells
Chen et al were the first to suggest that embryonic stem
cells (ESCs), embryoid bodies, and day 11 mouse
embryos exhibit a less complex miRNA profile than more
mature somatic tissues. They hypothesized that the degree
of cellular or tissue differentiation can be characterized by
a particular miRNA signature [10]. The obvious parallel
that can be drawn is that undifferentiated stem cells dis-
play miRNA expression profiles reminiscent of cancer
cells. Numerous known oncogenic miRNAs are expressed
in early stages of development in undifferentiated cells;
however, their expression decreases in differentiated tis-
sue, whereas the opposite holds true for tumor suppres-
sive miRNAs.
In recent years, there has been a sudden increase in studies
on a subpopulation of cells in tumors that have stem cell
properties, cancer stem cells (CSCs). The CSC hypothesis
proposes that cancers are derived from a small fraction of
cancer cells that constitute a reservoir of self-sustaining
cells with the exclusive ability to self-renew and maintain
the tumor. Small numbers of CSCs are sufficient to form
orthotopic tumors in vivo. Cells which could be described
as CSCs have been isolated from hematological malignan-
cies, brain, breast and colon tumors [6,7,11-13].
GBM-derived CSCs share the fundamental stem cell prop-
erties of self-renewal and multi-potency with neural stem
cells (NSCs). They were first isolated from tumors by vir-
tue of the expression of CD133 that marks NSCs and neu-
ral progenitor cells (NPCs) [6,7]. Microarray studies have
since revealed considerable overlap between the gene-
expression signatures of glioblastomas and progenitor
cells of the developing forebrain. Forced differentiation of
CD133+ cells with BMP4 addition abrogates their stem
cell phenotypes, making this a potential therapeutic
approach for eliminating this subpopulation of GBMs [7].
In the study published by Silber et al, two miRNAs with
low expression in GBMs and AAs, miR-124 and miR-137,
increase in expression upon differentiation of mouse
NSCs with growth factor withdrawal (Figure 2). Interest-
ingly, the expression of miR-124, which is a brain
enriched miRNA, has been shown to correlate with the
first appearance of differentiated neurons in culture from
NPCs [14]. Overexpression of these two miRNAs in undif-
ferentiated mNSCs, mouse oligodendroglioma-derived
stem cells and CSCs termed human GBM-derived stem
cells (hGSCs) led to morphological changes and expres-
sion of markers indicating neuronal differentiation (Fig-
ure 2). The forced differentiation of these CSCs which is
mediated by these two miRNAs leads to loss of their self-
renewal and oncogenic capacity. These data are in accord-
ance with previous approaches where CSC oncogenicity
was severely disrupted by differentiation. A challenge in
this field is to define the functional, molecular, regulatory
and antigenic features that characterize NPCs from CSCs
and ultimately to devise therapeutic strategies that specif-
ically target the tumor population, but leave normal stem
and precursor cells unharmed.
Treatment of GBM tumors with current methods has
proven largely unsuccessful. To a great extent this is
because of the ineffectiveness of current therapeutics to
target the CSC population of GBM tumors. This study
indicates a new approach targeting the CSC subpopula-
tion of tumors by overexpressing microRNAs which are
normally expressed in the surrounding differentiated tis-
sue. Upregulation of miR-124 and miR-137 could have
therapeutic use in blocking this CSC subpopulation of
GBM tumors. Modulation of GBM tumor dysregulated
mir-137 and mir-124 are essential for the canonical differen- tiation of neural stems cells and neural progenitor cells Figure 2
mir-137 and mir-124 are essential for the canonical 
differentiation of neural stems cells and neural pro-
genitor cells. Abrogation of their expression could lead to 
cancer stem cell (CSC) formation and tumorogenesis. Upreg-
ulation of these two microRNAs in CSCs could present a 
therapeutic approach in differentiating these cells, thus elimi-
nating their stem cell properties.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2008, 6:15 http://www.biomedcentral.com/1741-7015/6/15
Page 4 of 4
(page number not for citation purposes)
miRNAs such as miR-21 and miR-124/miR-137 by RNAi-
based therapeutics, in conjunction with current treat-
ments may prove a key approach in the fight against these
deadly tumors.
Development of miRNA/RNAi-based therapeutics
requires several critical experimental steps, which include:
(1) miRNA profiling of cancer versus healthy tissue, (2)
functional analysis of dyregulated miRNAs, and (3) in vivo
studies with use of different RNAi-based therapeutic
methods to dysregulate miRNAs. Silber et al have per-
formed the two initial steps for miR-124/miR-137 as ther-
apeutic targets in GBMs. A major caveat in RNAi-based
therapeutics has been their in vivo targeting to the brain
and particularly crossing of the blood brain barrier [15].
This problem can be overcome with the use of lipid
encapsulation, direct administration of the therapeutics to
the brain tumor or development of safe gene therapy
approaches using viral delivery [15]. In the dawn of
miRNA research, there is confidence that RNAi can be suc-
cessfully maintained in vivo in a tumor-specific manner
for prolonged clinical efficacy. The success of such strate-
gies for gene therapy will provide clinicians with a larger
repertoire that includes miRNA-therapeutic agents, which
can be used in parallel with currently available drugs.
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